Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | GLP1R | P43220 | 1/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 1.00 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 1.00 |
| ▸ | CNR2 | P34972 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454849 | 0.93 | CNR1 (1.00) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5459855 | 0.92 | CNR1 (0.85) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5469436 | 0.91 | CNR1 (1.00) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5468091 | 0.86 | CNR1 (0.83) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5459428 | 0.85 | CNR1 (0.83) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL1316265 | 0.84 | CNR1 (1.00) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5461341 | 0.83 | CNR1 (0.85) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL1846007 | 0.83 | CNR1 (0.73) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5555792 | 0.83 | CNR1 (0.89) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL17645268 | 0.82 | CNR1 (0.68) | CNR1ADRB2ADRA2AAGTR1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | BRANDT THOMAS A | 2007-11-08 | — | — | US | claimed |
| EP-1797041-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2007060525-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | claimed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2006035310-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | claimed |
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | disclosed |
| US-20240410010-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2024-12-12 | — | — | US | disclosed |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-12104209-B2 | Non-invasive diagnostic of non-alcoholic steatohepatitis | GENFIT (FR) | 2024-10-01 | — | — | US | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20240282454-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2024-08-22 | — | — | US | disclosed |
| CN-115677511-B | Synthesis method of 2, 2-difluoropropylamine hydrochloride | 南通华祥医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4366696-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | Gannex Pharma Co., Ltd. (CN) | 2024-05-15 | — | — | EP | disclosed |
| EP-4355915-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | Genfit (FR) | 2024-04-24 | — | — | EP | disclosed |
| CN-117915891-A | Combination therapy for the treatment of liver diseases | 甘莱制药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117915914-A | Combination therapy for treating liver diseases | 甘莱制药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-111065748-B | Non-invasive diagnosis of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and/or liver fibrosis | 基恩菲特公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3436600-B1 | NON-INVASIVE DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-109072302-B | Non-invasive diagnosis of non-alcoholic steatohepatitis | 基恩菲特公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11676269-B2 | Automated pattern recognition and scoring method of histological images | GENFIT (FR) | 2023-06-13 | — | — | US | disclosed |
| CN-115677511-A | Synthetic method of2, 2-difluoropropylamine hydrochloride | 南通华祥医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023280152-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280150-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2023-01-12 | — | — | WO | disclosed |
| CN-110536682-B | Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents | 基恩菲特公司 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022263565-A1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2022-12-22 | — | — | WO | disclosed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11484517-B2 | Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor | GENFIT (FR) | 2022-11-01 | — | — | US | disclosed |
| US-11478440-B2 | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent | GENFIT (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20220241232-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | GENFIT (FR) | 2022-08-04 | — | — | US | disclosed |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2022-05-26 | — | — | US | disclosed |
| EP-3985126-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | Genfit (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| EP-2321351-B1 | ANTIBODIES TO CCR2 | PFIZER (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9238691-B2 | Nucleic acids encoding antibodies to CCR2 | PFIZER INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | AMGEN FREMONT INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8710191-B2 | Antibodies to CCR2 | PFIZER INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20110274696-A1 | ANTIBODIES TO CCR2 | AMGEN FREMONT INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7935342-B2 | Methods for treating obesity by administering a trkB antagonist | RINAT NEUROSCIENCE CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100008933-A1 | Methods For Treating Obesity By Administering A TRKB Antagonist | RINAT NEUROSCIENCE CORP. | 2010-01-14 | — | — | US | disclosed |
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | disclosed |
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2078729-A1 | PPY agonists and uses thereof | Pfizer Products Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090171071-A1 | PYY Agonists and Uses Thereof | PFIZER INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170778-A1 | PYY Agonists and Uses Thereof | PFIZER INC. | 2009-07-02 | — | — | US | disclosed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009056934-A1 | 1,4-DIHYDRONAPHTHYRIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-1846445-B1 | PYY AGONISTS AND USES THEREOF | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1988920-A1 | METHODS FOR TREATING OBESITY BY ADMINISTERING A TRKB ANTAGONIST | Rinat Neuroscience Corp. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | disclosed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | BRANDT THOMAS A | 2007-11-08 | — | — | US | disclosed |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | BRANDT THOMAS A | 2007-11-08 | — | — | US | disclosed |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | BRANDT THOMAS A | 2007-11-08 | — | — | US | disclosed |
| EP-1846445-A1 | PYY AGONISTS AND USES THEREOF | Pfizer Products Incorporated (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007060525-A3 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PROD INC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007088479-A1 | METHODS FOR TREATING OBESITY BY ADMINISTERING A TRKB ANTAGONIST | RINAT NEUROSCIENCE CORP. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007085887-A1 | PYY AGONISTS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007079317-A2 | USE OF SEDATIVE HYPNOTICS FOR TREATING OBESITY OR MAINTAINING WEIGHT LOSS | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1797041-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007060525-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060525-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060525-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007039797-A1 | USE OF CANNABINOID RECEPTOR-1 ANTAGONIST FOR TREATING INFLAMMATION AND ARTHRITIS | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | disclosed |
| US-20060178501-A1 | PYY agonists and use thereof | PFIZER INC | 2006-08-10 | — | — | US | disclosed |
| WO-2006082517-A1 | PYY AGONISTS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006035310-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | CNR1 13/4885ADRB2 37/4885ADRA2A 35/4885 |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | CCR2, CCR1, CCR5 | CNR1 1110/4885ADRB2 1947/4885ADRA2A 1408/4885 |
| US-11478440-B2 | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent | FABP1, HDGF, HGF | CNR1 2289/4885ADRB2 2777/4885ADRA2A 3181/4885 |
| US-20090171071-A1 | PYY Agonists and Uses Thereof | NPY1R, NPY2R, NPY4R | CNR1 147/4885ADRB2 224/4885ADRA2A 136/4885 |
| US-20220241232-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | SLC10A1, CPT1A, FABP1 | CNR1 512/4885ADRB2 652/4885ADRA2A 727/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885ADRB2 433/4885ADRA2A 101/4885 |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885ADRB2 100/4885ADRA2A 244/4885 |
| US-20240325417-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | PYGL, GYS2, OAT | CNR1 2903/4885ADRB2 1484/4885ADRA2A 1765/4885 |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885ADRB2 100/4885ADRA2A 244/4885 |
| US-20110274696-A1 | ANTIBODIES TO CCR2 | CCR2, CCR1, CCR5 | CNR1 1164/4885ADRB2 1614/4885ADRA2A 1068/4885 |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | CNR1 1652/4885ADRB2 1412/4885ADRA2A 1654/4885 |
| US-20240410010-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | CNR1 2438/4885ADRB2 2929/4885ADRA2A 3494/4885 |
| US-11484517-B2 | Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor | ACACA, PPARA, PPARG | CNR1 466/4885ADRB2 451/4885ADRA2A 400/4885 |
| US-20090170778-A1 | PYY Agonists and Uses Thereof | NPY1R, NPY2R, NPY4R | CNR1 147/4885ADRB2 224/4885ADRA2A 136/4885 |
| US-12104209-B2 | Non-invasive diagnostic of non-alcoholic steatohepatitis | FABP1, SLC10A1, FABP2 | CNR1 2438/4885ADRB2 2929/4885ADRA2A 3494/4885 |
| US-20060178501-A1 | PYY agonists and use thereof | NPY1R, NPY4R, NPY2R | CNR1 150/4885ADRB2 216/4885ADRA2A 134/4885 |
| US-20070260056-A1 | Process for Preparing Bicyclic Pyrazolyl | CNR1, CNR2, GPR18 | CNR1 1/4885ADRB2 116/4885ADRA2A 188/4885 |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | CNR1 116/4885ADRB2 38/4885ADRA2A 28/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | CNR1 1908/4885ADRB2 808/4885ADRA2A 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.